JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Scope & Guideline

Elevating ophthalmic therapies for a brighter future.

Introduction

Delve into the academic richness of JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1080-7683
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1985 to 2024
AbbreviationJ OCUL PHARMACOL TH / J. Ocular Pharmacol. Ther.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The Journal of Ocular Pharmacology and Therapeutics focuses on advancing the field of ocular pharmacology through innovative research and clinical studies. It encompasses a wide range of topics that combine pharmacological approaches with therapeutic interventions for various ocular diseases.
  1. Ocular Drug Development and Delivery Systems:
    The journal emphasizes novel drug delivery systems and formulations designed to enhance the efficacy and safety of ocular therapeutics. This includes research on nanotechnology, polymeric micelles, and sustained-release systems.
  2. Pharmacological Therapies for Ocular Diseases:
    A core focus is on pharmacological treatments for conditions such as glaucoma, dry eye disease, and retinal disorders. This involves both systemic and topical therapies, as well as the evaluation of new pharmacological agents.
  3. Mechanisms of Disease and Pathophysiology:
    Research articles often explore the underlying mechanisms of ocular diseases, including neurodegeneration, inflammation, and fibrosis. Understanding these mechanisms is crucial for developing targeted therapies.
  4. Clinical Trials and Efficacy Studies:
    The journal publishes findings from clinical trials that assess the safety and efficacy of new treatments in human subjects, providing valuable insights into real-world applications of ocular therapeutics.
  5. Innovative Therapeutic Modalities:
    The journal includes studies on gene therapy, stem cell therapy, and other cutting-edge approaches aimed at regenerating ocular tissues and restoring vision.
The Journal of Ocular Pharmacology and Therapeutics is witnessing several emerging trends that reflect the evolving landscape of ocular research and therapy.
  1. Nanotechnology and Advanced Drug Delivery:
    There is a growing trend towards exploring nanotechnology and advanced drug delivery mechanisms, with studies focusing on how these innovations can improve therapeutic outcomes in ocular diseases.
  2. Biologics and Targeted Therapies:
    Research on biologics, including monoclonal antibodies and gene therapies, is increasing. These therapies offer targeted approaches to treat complex ocular conditions, such as age-related macular degeneration and diabetic retinopathy.
  3. Regenerative Medicine:
    An emerging focus on regenerative medicine techniques, including stem cell therapy and tissue engineering, is evident. This reflects a broader interest in restoring function and repairing damaged ocular tissues.
  4. Personalized Medicine Approaches:
    The journal is increasingly publishing studies that emphasize personalized medicine, tailoring treatments based on individual patient characteristics and disease profiles.
  5. Ocular Safety and Toxicology Studies:
    There is a notable increase in research dedicated to evaluating the safety and toxicological profiles of new ocular therapies, addressing concerns about long-term effects and patient safety.

Declining or Waning

While the Journal of Ocular Pharmacology and Therapeutics continues to thrive in many areas, some themes appear to be declining in prominence based on recent publications.
  1. Traditional Pharmacological Agents:
    There is a noticeable decrease in studies focusing solely on traditional pharmacological agents, such as older classes of eye drops and systemic medications, as the field shifts towards more innovative therapies.
  2. Invasive Surgical Techniques:
    Research on invasive surgical techniques for treating ocular diseases is diminishing in frequency. The trend is moving towards less invasive options and pharmacological alternatives.
  3. General Reviews without Novel Insights:
    The prevalence of general review articles that do not provide novel insights or data is declining, as the journal increasingly prioritizes original research that contributes new knowledge to the field.

Similar Journals

MOLECULAR VISION

Transforming knowledge into vision-enhancing solutions.
Publisher: MOLECULAR VISIONISSN: 1090-0535Frequency: 1 issue/year

MOLECULAR VISION is a premier open-access journal that has been advancing the field of ophthalmology since its inception in 1995. Published by MOLECULAR VISION, this journal boasts a strong reputation, currently ranking in the second quartile (Q2) of its category, with a Scopus ranking of 35 out of 137, placing it in the 74th percentile among peer publications. Dedicated to disseminating groundbreaking research and innovative findings in the study of vision and ocular health, MOLECULAR VISION serves as a vital resource for researchers, healthcare professionals, and students engaged in this dynamic field. The journal welcomes contributions spanning fundamental and clinical research, offering a platform for crucial knowledge exchange that is essential for advancing ocular health and function. With its commitment to open access, readers around the globe can freely access and build upon the wealth of information disseminated through its pages, ensuring that the latest developments in ophthalmology are available to all.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Elevating clinical practice with innovative pharmacotherapy findings.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Transforming Knowledge into Visionary Practice
Publisher: SPRINGERISSN: 0721-832XFrequency: 12 issues/year

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.

Ocular Surface

Illuminating Insights in Ophthalmology
Publisher: ELSEVIERISSN: 1542-0124Frequency: 4 issues/year

Ocular Surface, published by Elsevier, stands at the forefront of ophthalmology research, with a notable Impact Factor reflecting its significant contribution to the field. As a vibrant platform for disseminating cutting-edge findings, this journal has achieved Q1 ranking in the Ophthalmology category as of 2023, placing it amongst the top-tier journals globally, specifically ranking 4th out of 137 in Scopus with an impressive 97th percentile. Spanning across the years from 2003 to 2024, Ocular Surface focuses on advancing knowledge in areas such as ocular pathology, therapy, and surgical interventions. While the journal is not open access, it provides invaluable insights and empirical data essential for researchers, professionals, and students dedicated to improving ocular health. With an address rooted in Amsterdam, Netherlands, this esteemed journal continues to enrich the global conversation in ophthalmology.

OPHTHALMIC RESEARCH

Connecting Researchers for a Brighter Future in Eye Health
Publisher: KARGERISSN: 0030-3747Frequency: 6 issues/year

Ophthalmic Research, with ISSN 0030-3747 and E-ISSN 1423-0259, is a distinguished peer-reviewed journal published by Karger in Switzerland. Established in 1970, this journal serves as a vital resource for exploration and dissemination of knowledge within the fields of Ophthalmology, Cellular and Molecular Neuroscience, and Sensory Systems, maintaining its relevance through its convergence into modern research methodologies leading up to 2024. With impressive rankings in 2023, it holds a Q2 quartile in both Ophthalmology and Medicine (miscellaneous), reflecting its significant contribution to the academic community, alongside Scopus ranks that position it favorably in the competitive landscape of medical and neuroscientific literature. Although not open access, the journal ensures that high-quality research remains accessible to its readership, which includes researchers, professionals, and students eager to stay at the forefront of ophthalmic advancements. By fostering interdisciplinary collaboration and facilitating high-level discourse, Ophthalmic Research is pivotal for those committed to advancing the future of eye care and vision sciences.

CLINICAL THERAPEUTICS

Exploring the intersection of research and clinical excellence.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Exploring the intersection of fundamental research and clinical application.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

DRUGS

Exploring Innovative Drug Discoveries
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Translational Vision Science & Technology

Elevating Research in Vision Science and Biomedical Engineering
Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INCISSN: 2164-2591Frequency: 6 issues/year

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

Journal of Ophthalmic & Vision Research

Advancing the Frontiers of Eye Care
Publisher: KNOWLEDGE EISSN: 2008-2010Frequency: 4 issues/year

The Journal of Ophthalmic & Vision Research, published by KNOWLEDGE E, stands as a crucial platform for disseminating high-quality research in the field of ophthalmology. With an ISSN of 2008-2010 and an E-ISSN of 2008-322X, this journal fosters open access to valuable insights since 2010, enhancing visibility and reach for researchers globally. Based in Dubai, UAE, it has established a reputation for excellence, reflected in its Q2 ranking in Ophthalmology for 2023 and its position among the top 65th percentile in Scopus. Covering a broad spectrum of topics within ophthalmic science, the journal serves as a vital resource for professionals, researchers, and students by presenting original research, reviews, and case studies that drive innovation and collaboration within the community. As the journal continues to contribute to advancements in eye care and vision sciences, it invites scholars to explore, engage, and publish within its pages, thus enriching the global discourse on ophthalmic health.